BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36088091)

  • 1. The Oracle of the Auricle?: Optimizing Serial Risk Stratification of Patients With Pulmonary Arterial Hypertension.
    Shelburne NJ; Frantz RP
    Chest; 2022 Sep; 162(3):509-510. PubMed ID: 36088091
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective.
    Humbert M; Lau EMT
    Am J Respir Crit Care Med; 2021 Mar; 203(6):675-677. PubMed ID: 33357026
    [No Abstract]   [Full Text] [Related]  

  • 3. The Clinical Value of Proposed Risk Stratification Tools in Pediatric Pulmonary Arterial Hypertension.
    Haarman MG; Douwes JM; Ploegstra MJ; Roofthooft MTR; Vissia-Kazemier TR; Hillege HL; Berger RMF
    Am J Respir Crit Care Med; 2019 Nov; 200(10):1312-1315. PubMed ID: 31298925
    [No Abstract]   [Full Text] [Related]  

  • 4. Gaps of evidence in pulmonary arterial hypertension.
    Vizza CD; Ghio S; Badagliacca R; Manzi G; Scelsi L; Argiento P; D'Alto M
    Int J Cardiol; 2022 Oct; 364():119-123. PubMed ID: 35716936
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic Stratification and Treatment for Pulmonary Arterial Hypertension. Gaps and Promising Remedies.
    Del Pozo R; Cruz-Utrilla A; Escribano-Subias P
    Arch Bronconeumol; 2023 Oct; 59(10):617-618. PubMed ID: 37147267
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of serial right heart catheterization in risk stratification and management of pulmonary arterial hypertension.
    Sharma D; Shah RJ; Sreenivasan J; Kafle P; Gupta R; Levine A; Lanier GM; Aronow WS
    Expert Rev Cardiovasc Ther; 2022 Jul; 20(7):543-547. PubMed ID: 35726644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prime Time for Proteomics in Pulmonary Arterial Hypertension Risk Assessment?
    Singh N; Ventetuolo CE
    Am J Respir Crit Care Med; 2022 May; 205(9):988-990. PubMed ID: 35143371
    [No Abstract]   [Full Text] [Related]  

  • 8. Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables.
    Pausch C; Pittrow D; Hoeper MM; Huscher D
    Eur Respir J; 2023 Nov; 62(5):. PubMed ID: 37802633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Stratification in Pulmonary Arterial Hypertension: Perhaps Simple Is Not Best?
    Fauvel C; White RJ; Vanderpool RR; Badagliacca R; Tobore T; Rahman M; Vizza CD; Lin S; Everett AD; Visovatti SH; Benza RL
    Chest; 2024 Feb; 165(2):431-436. PubMed ID: 37709252
    [No Abstract]   [Full Text] [Related]  

  • 10. The Pursuit of Risk Assessment and Stratification Tools in Pulmonary Arterial Hypertension: Have We Seen the Lite?
    Ford HJ; LeVarge B
    Chest; 2021 Jan; 159(1):14-16. PubMed ID: 33422195
    [No Abstract]   [Full Text] [Related]  

  • 11. Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation.
    Olsson KM; Richter MJ; Kamp JC; Gall H; Ghofrani HA; Fuge J; Ewert R; Hoeper MM
    Eur Respir J; 2022 Aug; 60(2):. PubMed ID: 35144993
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk scores as a surrogate in pulmonary arterial hypertension: a different lens.
    White RJ; Lachant DJ; Benza RL
    Lancet Respir Med; 2024 Mar; 12(3):e9-e10. PubMed ID: 38423704
    [No Abstract]   [Full Text] [Related]  

  • 13. Against the Odds: Risk Stratification with Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension.
    Richter MJ; Tello K
    Am J Respir Crit Care Med; 2020 Feb; 201(4):403-405. PubMed ID: 31726011
    [No Abstract]   [Full Text] [Related]  

  • 14. Cross-cultural validation of the Chinese version of the EmPHasis-10 questionnaire in connective tissue disease patients with pulmonary arterial hypertension and its relationship with risk stratification.
    Shi Y; Dong X; Hu X; Weng L; Liu Y; Lai J; Tian Z; Zhao J; Li M; Peng J; Wang Q; Zeng X
    BMC Pulm Med; 2022 Jul; 22(1):264. PubMed ID: 35790938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Risk Stratification Scores in Pulmonary Arterial Hypertension: A Monocentric Retrospective Study at Lausanne University Hospital.
    Vraka A; Yerly P; Aubert JD
    Respiration; 2022; 101(6):565-576. PubMed ID: 35045412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where's the Easy Button? The Many Barriers to Care for Patients With Pulmonary Arterial Hypertension.
    Cantres-Fonseca O; Kennedy JLW
    J Am Heart Assoc; 2022 Nov; 11(22):e027967. PubMed ID: 36370008
    [No Abstract]   [Full Text] [Related]  

  • 17. [Risk stratification methods and their significance in pulmonary arterial hypertension].
    Avdeev SN; Tsareva NA
    Ter Arkh; 2019 Sep; 91(9):150-157. PubMed ID: 32598827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing Risk Stratification in Pulmonary Arterial Hypertension Through Cardiac MRI: The Need for Collaboration and Standardization.
    Frantz RP; Swift AJ
    Chest; 2024 Jan; 165(1):12-13. PubMed ID: 38199727
    [No Abstract]   [Full Text] [Related]  

  • 19. Call it by the correct name-pulmonary hypertension not pulmonary arterial hypertension: growing recognition of the global health impact for a well-recognized condition and the role of the Pulmonary Vascular Research Institute.
    Corris PA; Seeger W
    Am J Physiol Lung Cell Mol Physiol; 2020 May; 318(5):L992-L994. PubMed ID: 32233785
    [No Abstract]   [Full Text] [Related]  

  • 20. Sotatercept as a next-generation therapy for pulmonary arterial hypertension: insights from the STELLAR trial.
    Kopeć G
    Cardiovasc Res; 2023 Dec; 119(16):e155-e157. PubMed ID: 37584249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.